Ucb Sa Stock Fundamentals
| UCBJF Stock | USD 174.00 1.00 0.57% |
UCB SA fundamentals help investors to digest information that contributes to UCB SA's financial success or failures. It also enables traders to predict the movement of UCB Pink Sheet. The fundamental analysis module provides a way to measure UCB SA's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to UCB SA pink sheet.
UCB |
UCB SA Company Return On Equity Analysis
UCB SA's Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Current UCB SA Return On Equity | 0.11 |
Most of UCB SA's fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, UCB SA is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
| Competition |
Based on the latest financial disclosure, UCB SA has a Return On Equity of 0.1069. This is 100.45% lower than that of the Healthcare sector and 100.29% lower than that of the Biotechnology industry. The return on equity for all United States stocks is 134.48% lower than that of the firm.
UCB SA Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining UCB SA's current stock value. Our valuation model uses many indicators to compare UCB SA value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across UCB SA competition to find correlations between indicators driving UCB SA's intrinsic value. More Info.UCB SA is rated first in return on equity category among its peers. It is rated first in return on asset category among its peers reporting about 0.44 of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for UCB SA is roughly 2.28 . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the UCB SA's earnings, one of the primary drivers of an investment's value.Did you try this?
Run CEOs Directory Now
CEOs DirectoryScreen CEOs from public companies around the world |
| All Next | Launch Module |
UCB Fundamentals
| Return On Equity | 0.11 | |||
| Return On Asset | 0.0468 | |||
| Profit Margin | 0.15 % | |||
| Operating Margin | 0.19 % | |||
| Current Valuation | 17.07 B | |||
| Shares Outstanding | 189.96 M | |||
| Shares Owned By Insiders | 38.03 % | |||
| Shares Owned By Institutions | 40.78 % | |||
| Price To Earning | 17.62 X | |||
| Price To Book | 1.52 X | |||
| Price To Sales | 2.50 X | |||
| Revenue | 5.78 B | |||
| Gross Profit | 4.34 B | |||
| EBITDA | 1.59 B | |||
| Net Income | 1.06 B | |||
| Cash And Equivalents | 515 M | |||
| Cash Per Share | 2.71 X | |||
| Total Debt | 1.97 B | |||
| Debt To Equity | 0.34 % | |||
| Current Ratio | 1.12 X | |||
| Book Value Per Share | 46.94 X | |||
| Cash Flow From Operations | 1.55 B | |||
| Earnings Per Share | 4.90 X | |||
| Price To Earnings To Growth | 6.17 X | |||
| Number Of Employees | 8.6 K | |||
| Beta | 0.34 | |||
| Market Capitalization | 15.88 B | |||
| Total Asset | 14.21 B | |||
| Retained Earnings | 3 B | |||
| Working Capital | (251 M) | |||
| Current Asset | 2.46 B | |||
| Current Liabilities | 2.71 B | |||
| Z Score | 4.8 | |||
| Annual Yield | 0.02 % | |||
| Net Asset | 14.21 B | |||
| Last Dividend Paid | 1.3 |
About UCB SA Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze UCB SA's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of UCB SA using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of UCB SA based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases. The company was incorporated in 1925 and is headquartered in Brussels, Belgium. Ucb SA operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 8600 people.
Currently Active Assets on Macroaxis
Other Information on Investing in UCB Pink Sheet
UCB SA financial ratios help investors to determine whether UCB Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in UCB with respect to the benefits of owning UCB SA security.